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Abstract
Islet transplantation, with the advent of the Edmonton protocol in 2000, has offered a sig-
nificant alternative for long-lasting treatment of type 1 diabetes. However, the immuno-
suppression required for transplantation has the cytotoxic effect on pancreatic islets, and 
thus limiting the long-term efficacy of the transplant. Immediate loss of islets after trans-
plant was also observed because of immediate blood-mediated inflammatory response 
(IBMIR), which kills islets transplanted in the liver through portal vein. There is also 
commonly a lack of microvascular blood supply to the transplanted islets. In this chap-
ter, we will review the variety of technologies used to protect transplanted islets against 
toxicity of immunosuppression, immune rejection, and inflammatory response. We will 
evaluate the mechanisms of these technologies and their progress in solving the chal-
lenges to islet transplantation. The technologies include encapsulation of transplanted 
islets in various polymers, transplants in sites other than the liver, and creation of new 
prevascularized transplant site. These technologies offer several mechanisms to prevent 
immune rejection or immediate contact with cytotoxic inflammatory response, in addi-
tion to maintaining islet integrity. New transplant sites are also being developed to sup-
port the islets, by allowing establishment of microvasculature and innervation, prior to 
addition of the islets.
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1. Introduction
Over 25 million people in the United States (USA) suffer from diabetes, with approximately 
5% characterized as type 1 diabetes (T1DM). Diabetes is ranked as the seventh leading cause 
of death in the USA. T1DM is characterized by the autoimmune-mediated destruction of the 
β-cells of the pancreas, resulting in insulin deficiency [1]. The current method of treatment for 
T1DM is insulin injection to maintain blood glucose control, which treats the symptoms but 
not the underlying disease.
With the invention of the Edmonton protocol in 2000, islet transplantation has become an 
attractive treatment for T1DM. As a treatment option, islet transplantation meets the goal of 
treating the disease rather than the symptoms. The end goal of islet transplantation in patients 
is the elimination of exogenous insulin dependence, allowing for those with T1DM to return to 
normal lives without constant monitoring of their blood glucose levels. There have been a total 
of 677 islet transplant recipients from 2000 to 2010. The success of the treatment has improved 
as well, where 27% of recipients achieved 3 years of insulin independence before 2007. After 
2007 that rate has increased to 44%. Compared to insulin injection regimen, islet transplanta-
tion resulted in significant reduction in episodes of hypoglycemia unawareness [2].
Islet transplantation faces two challenges from the host immune system: the rejection of 
the transplanted islets as foreign body and the existing autoimmunity against β-cells. 
Immunosuppressive drugs such as sirolimus and rapamycin used in the Edmonton protocol 
has toxic side effects on islets [3, 4]. As such, there is an impetus to move away from the use 
of immunosuppressive therapy and instead shift toward developing physical barriers against 
transplant rejection and autoimmunity.
Cell encapsulation to provide physical barrier has been tested in treating other diseases such 
as neurodegenerative diseases, pain, and epilepsy to name a few. So far, encapsulation has 
been used primarily to treat T1DM [5–9]. By providing a physical barrier to immune rejection, 
islet encapsulation has been shown to allow transplanted islet to function normally and avoid 
the use of immunosuppression [10, 11].
2. History of animal and human trials of islet encapsulation
The first encapsulated islet transplants occurred in 1980, where islets in an alginate hydrogel 
transplanted intraperitoneally into diabetic rats achieved normoglycemia for 3 weeks, com-
pared to 8 weeks for nonencapsulated islets [12]. Currently, there are a number of achievements 
in encapsulating islets seen in small and large animal studies, as well as in early phase clinical 
trials. A syngeneic transplant of nonobese diabetic (NOD) into prediabetic islets diabetic NOD 
recipients, using 5% agarose encapsulating 1500–2000 islet equivalents (IEq), showed that 
intraperitoneal implantation as well as omental pouch transplants demonstrated prolonged 
euglycemia for a period of 100 days compared to 8 days for unencapsulated islet transplants 
[13]. This study was repeated in 2006, where the same period of normoglycemia was observed 
in transplant recipients. In addition, when the devices were removed after 400 days, viable 
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islets were recovered with a small percentage of necrotic cells [14]. Aside from agarose, poly-
ethylene glycol-poly lactic-co-glycolic acid (PEG-PLGA) has been used to encapsulate 500–600 
IEq islets for syngeneic transplant into streptozotocin (STZ) induced diabetic BALB/c mice, 
where over half of the recipients achieved normal glucose levels for up to 100 days [15].
Results in large animal studies have mostly mirrored that of the small animal trials. Diabetic 
canine recipients, receiving 15,000–20,000 IEq islets/kg in alginate microcapsule into the intra-
peritoneal cavity, were able to maintain normoglycemia without insulin injection for up to 110 
days, with c-peptide detectable in the blood for more than 1 year [16]. In 2010, allogeneic trans-
plant in nonhuman primate was tested using subcutaneous and kidney capsule transplants of 
alginate micro and macroencapsulated islets, at a dose of 30,000 IEQ/kg. In this study, normo-
glycemia was observed for 28 weeks [17]. In a xenotransplant study of neonatal porcine islets 
into diabetic cynomolgus monkey, 10,000 IEq/kg of alginate encapsulated islets resulted in 
more than 40% reduction in injectable insulin dose compared to preimplantation [18].
The first human clinical trial of encapsulated islets transplant in T1DM was reported in 
1994. In a type 1 diabetes patient, a postoperative kidney transplant maintained on low dose 
immunosuppression initially received 10,000 IEQ/kg of cadaver human islets encapsulated 
in an alginate microcapsule followed by a repeat infusion of 5000 IEQ/kg 6 months later. The 
patient’s insulin requirements were reduced to 1–2 insulin units per day, and eventually he 
was able to discontinue all exogenous insulin after 9 months [19]. In 2006, human cadaveric 
islets (400,000–600,000 IEQ) were encapsulated into sodium alginate beads and placed intra-
peritoneally into two diabetic patients. The patients showed improved daily glucose levels 
and a decline in daily exogenous insulin intake. However, neither patient became insulin 
independent [20].
Living Cell Technologies Ltd. an Australia company has achieved the best outcomes for 
encapsulated islet transplants. The company, which owns a pathogen-free pig farm in New 
Zealand, performed xenotransplantation of alginate encapsulated fetal pig islets in several 
human clinical trials. The most significant achievement has been in the reduction of hypo-
glycemic episodes to around 40%. Several patients achieved improvements in daily glucose 
levels and a reduction in exogenous insulin dosing, while two patients became insulin inde-
pendent after 4 months [21, 22].
Unfortunately, there is a lack of consistency in the human clinical results. For example, a 
human clinical trial by Tuch et al. used alginate encapsulated human islets and tracked the 
presence of plasma C-peptide levels for up to 2.5 years, ultimately resulting in no change 
in insulin requirements for the recipients [23]. While these early phase clinical trials aim to 
ensure safety and determine optimal islet dose, most of the trial patients do not achieve sus-
tainable insulin independence.
3. Biomaterials used for islet encapsulation
One of the important steps to bring islet encapsulation into widespread clinical use is to 
develop a standard for the type of biomaterial used and the dose of islets to be infused. 
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The type of biomaterial has also been shown to affect graft survival. A test of several encap-
sulation methods using alginate with or without poly L-lysine (PLL) as well as with high 
guluronic (G) or mannuronic (M) acid in mouse recipients showed that significant results 
were achieved with PLL-free high M microcapsules, showing sustained normoglycemia for 
8 weeks [24]. Likewise, improved capsule integrity and graft function could be achieved by 
altering the concentration of alginate in their xenotransplants into diabetic Lewis rats [25].
Currently, the most common employed method for islet encapsulation involves alginate 
microcapsules [24, 26, 27]. The original device was developed over three decades ago as cap-
illary fibers in a culture-coated medium [28], shaped as arterial-venous shunts into diabetic 
canines. These devices showed promising results with several canines achieving reduced 
insulin requirements [29, 30]. Vascular shunts are limited by the volume and number of islets 
that can be contained within the fibers. Elongation of the fibers resulted in increased fibrosis, 
leading to abandonment of this device as the higher dose of islets needed for human recipi-
ents would require such large fibers that resulted in a large amount of fibrosis [31]. Other 
macroscale devices have seen less use due to their increased immunogenicity as well as the 
larger diffusion parameters required for oxygen and nutrients to reach the cell.
Nanoencapsulation has an advantage compared to other techniques because of its more effi-
cient diffusion capability. With a better surface area to volume ratio, this means that nanoen-
capsulation can improve insulin response time to blood glucose levels, offering the protection 
of encapsulation without compromising tissue function due to the physical barrier. PEG has 
been used for nanoencapsulation devices and can be cross-linked through exposure to UV 
or visible light. This characteristic also allows for a reduction in the amount of damage done 
to the capsule’s inner cells normally achieved by other cross-linking methods. On the other 
hand, PEG biocompatibility still leaves much to be desired compared to other hydrogels, and 
complete protection from cytokines is still not achieved [32]. Despite these concerns, some 
success has been attained with these gels [33].
By far the most common encapsulation device is a microscale vehicle. These capsules have 
mechanical stability, optimal surface area to volume ratio, and have enhanced immunologic 
profiles [26, 33]. Microscale device is also easily made using standard droplet-based encap-
sulators that produces consistent size and shape of the resulting capsules [34, 35], as shown 
in Figure 1.
Microcapsules can also be easily made using materials other than alginate. The most common 
synthetic chemicals used for microcapsule production are poly ethylene oxide, poly acrylic 
acid, poly vinyl alcohol, polyphosphazene, and polypeptides and their derivatives. Natural 
occurring hydrogels include gelatin, fibrin, agarose, hyaluronate, chitosan, and alginate [36, 
37]. Poly glycolic and lactic acid polymers continue to be the most commonly used synthetic 
materials used in medical devices.
Regardless of the materials used, capsule materials still face the fundamental flaw of being 
foreign materials. Thus there will always be the possibility they will elicit a greater immune 
response, eventually leading to fibrosis and loss of the encased cells. As such, it is important 
to ensure that the materials are nontoxic and purified prior to microcapsule production.
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Because of their tolerability, biologically derived materials have been of interest for islet 
encapsulation. One possible material is collagen, a naturally derived polymer that is the most 
widely used in medical devices today. However, collagen gels exhibit poor strength, which 
are expensive and have high variability of purity, making standardization of the process a 
problem [37]. Comparatively, alginate has excellent biocompatibility, hydrophilic properties, 
easy gelation process, stable architecture, and relatively low cost. Alginate is polysaccharide 
derived from seaweed, which can be highly purified to prevent foreign body response [38]. 
Impure alginate has been implicated in islet cell necrosis and recruitment of inflammatory 
mediators [39].
Alginate is a polymer of 1-4 linked β-D-mannuronic acid (M) and 1-4 linked α-L-guluronic 
acid (G). This polysaccharide can contain varying concentrations of M and G carbohydrates, 
which provides a variety of molecular weight, stability, permeability, and immunogenic-
ity. High G alginates form gels, which are smaller and stronger than high M alginates [38]. 
High-M alginate was often avoided when immunosuppression was the desired outcome, 
because mannuronic acid tends to provoke both innate and antibody-mediated immune 
response, independent of the type of cation used for cross-linking (Ca2+ or Ba2+). High-M also 
triggers macrophages to secrete pro-inflammatory cytokines including IL-1, IL-6, and TNF-α 
through interactions with the monocyte CD14 receptor [39]. However, recent studies seem 
to contradict these earlier findings, reporting a higher amount of cellular adhesion to high-G 
alginate capsules when compared to high-M alginate [40, 41]. It is likely that the observed 
difference in the immune response depends not on the identity of the alginate material, but 
instead on the quality of the alginate purification method [42, 43].
Using surface modification, poly-methyl co-guanidine-cellulose sulfate/poly l-lysine-sodium 
alginate (PMCG)-CS/PLL was used for syngeneic transplant into T1DM canine recipients [44]. 
Their study reported normoglycemia in the canines for approximately 160 days, with one 
canine achieving euglycemia for 214 days [45].
Figure 1. Porcine islet encapsulated in alginate. Isolated juvenile porcine islets (from 22 to 24 days old pigs, matured 
for 7 days) were encapsulated in 2.5% low viscosity mannuronate (Pro-Nova UPLVM) alginate (Novamatrix) using an 
electrostatic gas-driven encapsulator (Nisco Engineering AG).
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Alginate converts into a gel form by ionic cross-linking with bivalent cations such as calcium, 
magnesium, and more commonly barium [46]. Cross-linking establish a mesh of porous mate-
rial that allows bidirectional flow of materials, including oxygen, nutrients, and hormones 
(especially insulin). However, hydrogel polymerization does not result in uniform pore size, 
while internal permeability tends to vary between batches [38].
An increase in the degree of cross-linking results in gels that have superior mechanical 
strength but inversely reduces the size of the pores available for diffusion. It is possible to 
artificially organize the islets in alginate gels into clusters mimicking natural islets [47].
Surface modification using polycations and anions can change the permeability and mechanical 
strength of alginate, but the polarity tends to increase the immune response. Common molecules 
used for this purpose include: poly-d-lysine (PDL), polyethylene glycol (PEG), poly-L-ornithine 
(PLO), and poly-L-lysine (PLL). This effect can be counteracted by adding another layer of algi-
nate to prevent direct contact with a polar surface [38], or by modifying the alginate [48].
Capsule fibrosis was the most significant problem encountered when utilizing alginate cap-
sules [23, 49–51]. Theoretically, immune isolation is achieved by encapsulation of the cells, 
but some levels of immune rejection and foreign body response still occur. Also, while oxygen 
and nutrients are able to freely diffuse across a matrix, studies have shown that at the time of 
explant, histology showed a necrotic core in the encapsulated islets without evidence of fibro-
sis. This suggests inadequate oxygen diffusion into the center of the encapsulated islets [52].
The results demonstrated by these prior studies suggest that there are key points to be con-
sidered during engineering of the encapsulation vehicle. The raw and the purified capsule 
material must be nontoxic, while the purification method needs to be reproducible across 
batches. The polymerization of the capsule material needs to be noncytotoxic to the islets. If 
there is any degradation of the material, it must follow physiological tissue growth and its 
products must not adversely affect the coated cells or human body. For clinical application, it 
would be important for the capsule engineering to be easily scalable, while maintaining good 
manufacturing practices (GMP) adherence to satisfy regulatory standards.
4. Improvement on islet encapsulation engineering
4.1. Co-encapsulation
Co-encapsulation is the process of adding additional molecules to the capsule to enhance the 
performance of the encapsulated islets. Encapsulation of islets along with dexamethasone, a 
corticosteroid serving as local immune suppression, can improve islet survival in mice recipi-
ents compared to those islets alone [53]. In another study, co-encapsulation of mouse mono-
cyte macrophage cells and hamster kidney cells with ibuprofen improved the encapsulated 
cell survival both in vitro and in vivo [54].
While encapsulation protects the cells inside from large molecules such as antibodies as well as 
direct cellular contact, smaller molecules such as pro-inflammatory cytokines can still  diffuse 
across most hydrogel gradients due to their smaller molecular weight. To achieve this, an attempt 
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at islet encapsulation with a silicon nanopore membrane found observed cytokine protection and 
islet viability for over 6 hours, with the islets remaining responsive to glucose levels [55]. Thus, 
protection from these cytokines may promote capsule survival. In an in vitro study performed 
by Leung, capsules with anti-TNF alpha were able to remove active TNF-α, a pro-inflammatory 
cytokine from a culture medium, which resulted in better encapsulated cell survival [56].
4.2. Protection against hypoxia
In order to improve oxygen supply to the cell, access to a rich vascular bed is essential. 
Addition of the angiogenic factor, fibroblast growth factor 1 (FGF-1), into capsule was able to 
affect a continuous FGF-1 release for a 1-month period in vitro [57]. In another study, encap-
sulation of solid peroxide within polydimethylsiloxane resulted in sustained oxygen release 
from the matrix for approximately 6 weeks [58].
Extracellular matrix components, derived from laminin, have been shown to improve islet 
human islet function for encapsulated islet transplants. These extracellular matrix compo-
nents are also found in native islets located in the pancreas prior to islet isolation. In this case, 
a variety of laminin-derived peptides or collagen were co-encapsulated with human islets 
and islet function was measured in vitro. Islet viability and insulin response to glucose were 
improved by the addition of laminin-derived peptide or collagen [59].
4.3. Prevascularization
Prevascularization of islet implant consists of establishing a well-vascularized matrix or scaf-
fold, by implanting the scaffold, then encouraging angiogenesis that leads to scaffold pen-
etration by microcapillaries. Angiogenesis is promoted by addition of fibrin at the time of 
scaffold implant. Islets were then added to the scaffold after a certain duration that has been 
shown to allow significant vascularization, as shown in Figure 2. This method was shown to 
improve subcutaneous islet efficacy in restoring normoglycemia when compared to subcuta-
neous transplants of islets alone [60].
Figure 2. Prevascularized scaffold for islet transplant. Device is implanted subcutaneously 28 days before the 
introduction of the β-cell clusters during which the foreign body response and neovascularization are completed (A). 
The device contains polyethylene rods with high hydrophobicity to avoid cell adhesion. Upon removal of the rods, the 
islets can be infused (B).
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4.4. Toward GMP standard
One of the key issues facing the engineering of encapsulating material for islet transplanta-
tion would be to define standards for the materials. The standards required contain the choice 
of raw material, the purification method and quality control of the purification, the shape of 
the device used for encasing the islets, and the quality of the encased islets. The lack of such 
standards is likely to account for the current variability in the results reported in the literature 
on the encapsulated islet transplant.
As an example of the standard necessary for clinical translation of the encapsulation technol-
ogy, commercially available alginates used to create islet capsules have been found to contain 
pathogen-associated molecular patterns (PAMPS). PAMP such as peptidoglycan, lipoteichoic 
acid, and flagellin among other proteins, endotoxins, and polyphenols [61] can trigger rec-
ognition by the innate immune system. PAMPS are recognized by toll-like receptors (TLRs) 
and pattern-recognition receptors (PRRs) [61, 62], leading to pericapsular fibrotic overgrowth 
(PFO) [63] as the immune system attempts to isolate the graft. PFO severely hinders graft 
survival by preventing diffusion of nutrients and waste.
In addition to cellular adhesion and PFO, death of encapsulated islets may also be caused by 
chemokines and cytokines that are small enough to pass through the permeable capsules [64]. 
TLRs, upon recognition and binding of PAMPS to the receptor surface, initiate an intracellular 
signaling cascade ultimately resulting in the secretion of a host of inflammatory cytokines 
attributed to translocation of the NF-κB (nuclear factor kappa-light-chain-enhancer of acti-
vated B cells) into the nucleus [65].
Before alginate can be used for clinical transplantation, it will need further development in 
the GMP manufacturing and purification of the raw materials, to ensure a low amount of 
PAMP detectable by the recipient’s immune system. In addition, the production of the encap-
sulated islets, including the islet isolation and the encapsulation process, needs to achieve a 
threshold of standard of quality to ensure a consistent and reliable result, to make it possible 
to compare the effect of the variety of encapsulation techniques and improvements.
5. Conclusion
In this chapter, we have covered the variety of options used to protect transplanted islets 
physically against both transplant rejection and autoimmune assault on β-cells. The technolo-
gies covered include the variety of encapsulation devices, materials, and addition of support-
ive materials to improve islet function and survivability.
A key step toward translating biomaterial encapsulation of islets toward clinical trial would 
be to develop a standard of quality that has to be met by the raw encapsulation material, the 
islets, and the encapsulation process. This will eventually lead to a process that can be scaled 
up and to adhere to GMP quality requirements. The current variability of results in the litera-
ture on encapsulated islet transplants as T1DM treatment can likely be explained by the lack of 
such standard, making it impossible to reliably compare multiple encapsulation technologies.
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The results in the literature on the encapsulation of islets for the treatment of T1DM showed 
that it is a promising technology that can revolutionize the treatment paradigm for diabet-
ics. Although significant advances have occurred, there are several obstacles that must be 
addressed before achieving widespread use of this technology.
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